Apoglyx is a pre-clinical stage biotech company with the aim to develop a small molecule therapy for sepsis, and further indications, based on inhibition of Aquaporin-9.
Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).
Location: Sweden, Scania, Lund
Member count: 1-10
Founded date: 2015
Investors 1
| Date | Name | Website |
| 03.11.2021 | Almi Inves... | almi.se |